

PATENT Attorney Docket No. P03986US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Burkhard Göke

Group Art Unit:

SERIAL NO:

09/719,410

Examiner:

FILED:

December 12, 2000

Confirmation No:

TITLE:

GLUCAGON-LIKE PEPTIDE-1 IMPROVES THE ABILITY OF THE

B-CELL TO SENSE AND RESPOND TO GLUCOSE IN SUBJECTS WITH

IMPAIRED GLUCOSE TOLERANCE

INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This information disclosure statement is being filed *before* the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of the listed references are enclosed. The Examiner is requested to consider the references and make them of record.

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Applicant elects the option to pay the fee set forth in 37 C.F.R. sec 1.17(p) for submission of an information disclosure statement under § 1.97(c). A check in the amount of \$240.00 is enclosed.

CERTIFICATE OF MAILING

I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this 6th day of March, 2001.

Edmund J. Sease

Authorization is hereby made to charge any additional fees required by this paper or credit any overpayment to Deposit Account 26-0084. A duplicate of this paper is attached.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,

03/19/2001 UEDUVIJE 00000130 09719410

01 FC:126

180.00 OP

Regin. Ref: 03/19/2001 UEDUVIJE 0012213600 DAH:260084 Hame/Number:09719410 FC: 704 \$60.00 CR

- EJS/rl -

Edmund J. Sease, Reg. No. 24,741

ZARLEY, McKEE, THOMTE, VOORHEES

& SEASE

801 Grand Avenue, Suite 3200

Des Moines, Iowa 50309-2721

Phone No. (515) 288-3667

Fax No. (515) 288-1338

CUSTOMER NO: 22885

Attorneys of Record

Please type a plus sign (+) inside this box	Please	type a	plus sig	gn (+)	inside	this	box_
---	--------	--------	----------	--------	--------	------	------

MAR 1 2 200

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO **INFORMATION DISCLOSURE**

STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

Sheet of

Complete if Known			
Application Number	09/719,410		
Filing Date	December 12, 2000		
First Named Inventor	Burkhard Goke et al.		
Group Art Unit			
Examiner Name			
Attorney Docket Number	P03986US2		

	U.S. PATENT DOCUMENTS							
		U.S. Patent Document			Date of Publication of	on of Pages, Columns, Lines,		
Examiner Initials	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
-			- 					
	-							
		-						
				·····				
								

	FOREIGN PATENT DOCUMENTS							
Examiner	Examiner Initials Cite No.1 Cite Office3 Number4 (If known) Name of Patentee or Applicant of Cited Document	ļ	Foreign Patent Do			Date of Publication of Cited Document	AAUGLE KRIEASUT	
Initials*		MM-DD-YYYY	Passages or Relevant Figures Appear	T6				
	1		W0 98 08531 A		Eli Lilly and Company	1998-03-05	pgs. 23-24	\square
								╀╌┨
								┼┤
								┼╌┨
-		├	. /			 		
		$\vdash \dashv$				···		
-		\vdash						
			-					

Examiner	Date	
Signature	Considere	d
J. J		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2 Sheet

Complete if Known			
Application Number	09/719,410		
Filing Date	December 12, 2000		
First Named Inventor	Burkhard Goke et al.		
Group Art Unit			
Examiner Name			
Attorney Docket Number	P03986US2		

<u>6</u>			
E		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	2	RACHMAN J ET AL: "Near-normalisation of diurnal goucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM." DIABETOLOGIA, (1997 FEB) 40 (2) 205-11., XP002122529	
	3	CAVAGHAN M K ET AL: "Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance." JOURNAL OF CLINICAL INVESTIGATION, (1997 AUG 1) 100 (3) 530-7., XP002122530 the whole document	
	4	BYRNE M M ET AL: "Glucagon - like peptide 1 improves the ability of the beta - cell to sense and respond to glucose in subjects with impaired glucose tolerance." DIABETES, (1998 AUG) 47 (8) 1259-65., XP002122530 the whole document	
		·	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.